Predictors for prognosis of chronic myelocytic leukemia.
Bone marrows from 30 newly diagnosed Ph+chronic myelocytic leukemia (CML) (21 in chronic phase, CML-CP, 9 in accelerate phase, CML-AP) and 8 followed up patients in blast crisis (CML-BC) were tested by DNA strand breaks (%D value), DNA-aneuploidy, flow cytometry-cell surface antigen expression for CD15 and HLA-DR ratio. Our results showed that all these three parameters changed as the disease escalated. A very low value of %D and DNA-aneuploidy occurrences were high risk factors. Cell surface antigen expression CD15 and HLA-DR ratio measurement was simple and reliable. The ratio < 1.0 appeared earlier than morphology clarifying CML-AP and should be followed up regularly.
Chen
S S
SS
Institute of Hematology, Beijing Medical University.
Zhang
H F
HF
Xue
W T
WT
Li
K
K
Wang
P
P
Lui
Y
Y
D000782:Aneuploidy; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D001752:Blast Crisis / Q000235:genetics / Q000276:immunology / Q000473:pathology; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D016256:Lewis X Antigen; D011379:Prognosis; D012307:Risk Factors
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D006684:HLA-DR Antigens; D016256:Lewis X Antigen